ProCE Banner Activity

Case Discussion: Relapsed ES-SCLC

Multimedia
Watch this short case-based video for an overview of the evolving systemic therapy options for the treatment of relapsed ES-SCLC.

Released: February 05, 2021

Expiration: February 04, 2022

Share

Faculty

Mark A. Socinski

Mark A. Socinski, MD

Director, Lung Cancer Section of the Division of Hematology/Oncology
Co-Director, UPMC Center for Excellence in Lung Cancer
Co-Director, Lung and Thoracic Malignancies Program
University of Pittsburgh Cancer Institute
University of Pittsburgh
Pittsburgh, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme Corp.

Learning Objectives

  • Plan treatment strategies for patients with extensive-stage SCLC that include immune checkpoint inhibitor combinations

Faculty Disclosure

Primary Author

Mark A. Socinski, MD

Director, Lung Cancer Section of the Division of Hematology/Oncology
Co-Director, UPMC Center for Excellence in Lung Cancer
Co-Director, Lung and Thoracic Malignancies Program
University of Pittsburgh Cancer Institute
University of Pittsburgh
Pittsburgh, Pennsylvania

Mark A. Socinski, MD, has disclosed that he has received funds for research support from AstraZeneca, Bristol-Myers Squibb, Genentech, Merck, Novartis, and Takeda and fees for non-CME/CE services from AstraZeneca, Bristol-Myers Squibb, Celgene, Genentech, Merck, and Novartis.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.

Jason J. Everly, PharmD

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer reports that his spouse has ownership interest in AstraZeneca.

Megan K. Murphy, PhD

Scientific Director

Megan K. Murphy, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.